Monte Rosa Therapeutics (GLUE)
(Real Time Quote from BATS)
$4.13 USD
-0.82 (-16.57%)
Updated May 21, 2024 02:44 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/8/24 |
---|---|
Current Quarter | -0.58 |
EPS Last Quarter | -0.53 |
Last EPS Surprise | 5.36% |
ABR | 1.00 |
Earnings ESP
|
1.74% |
---|---|
Current Year | -2.16 |
Next Year | -2.07 |
EPS (TTM) | -2.52 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 3.19M | 3.19M | 9.06M | 12.81M |
# of Estimates | 3 | 3 | 4 | 3 |
High Estimate | 4.40M | 4.40M | 16.67M | 17.77M |
Low Estimate | 1.00M | 1.00M | 1.10M | 4.00M |
Year ago Sales | 0.00M | 0.00M | NA | 9.06M |
Year over Year Growth Est. | NA | NA | NA | 41.47% |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.58 | -0.58 | -2.16 | -2.07 |
# of Estimates | 4 | 4 | 4 | 4 |
Most Recent Consensus | NA | -0.60 | -2.07 | -1.69 |
High Estimate | -0.54 | -0.50 | -1.95 | -1.51 |
Low Estimate | -0.60 | -0.64 | -2.47 | -3.02 |
Year ago EPS | -0.71 | -0.70 | -2.63 | -2.16 |
Year over Year Growth Est. | 18.31% | 17.14% | 17.87% | 3.94% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 1 | 2 | 3 | 2 |
Up Last 60 Days | 1 | 2 | 3 | 2 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 1 | 2 | 1 | 2 |
Down Last 60 Days | 1 | 2 | 1 | 2 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.58 | -0.58 | -2.16 | -2.07 |
7 Days Ago | -0.58 | -0.58 | -2.16 | -2.07 |
30 Days Ago | -0.59 | -0.59 | -2.25 | -2.17 |
60 Days Ago | -0.59 | -0.59 | -2.25 | -2.17 |
90 Days Ago | -0.67 | -0.72 | -2.43 | -2.29 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.57 | -0.58 | -2.16 | -2.07 |
Zacks Consensus Estimate | -0.58 | -0.58 | -2.16 | -2.07 |
Earnings ESP | 1.74% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.53 | -0.58 | -0.70 | -0.71 | NA |
Estimate | -0.56 | -0.57 | -0.75 | -0.72 | NA |
Difference | 0.03 | -0.01 | 0.05 | 0.01 | 0.02 |
Surprise | 5.36% | -1.75% | 6.67% | 1.39% | 2.92% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more